Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.90 |
| ▸ | GAK | O14976 | 4/20 | 0.90 |
| ▸ | KDR | P35968 | 3/20 | 0.90 |
| ▸ | ILK | Q13418 | 2/20 | 0.90 |
| ▸ | FLT1 | P17948 | 2/20 | 0.90 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.90 |
| ▸ | BUB1 | O43683 | 2/20 | 0.90 |
| ▸ | STK10 | O94804 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | LCK | P06239 | 2/20 | 0.90 |
| ▸ | LYN | P07948 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | SRC | P12931 | 2/20 | 0.90 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.90 |
| ▸ | FECH | P22830 | 2/20 | 0.90 |
| ▸ | FLT3 | P36888 | 2/20 | 0.90 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.90 |
| ▸ | PLK4 | O00444 | 1/20 | 0.90 |
| ▸ | CIT | O14578 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507409 | 1.00 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| SCHEMBL2435950 | 1.00 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| SCHEMBL29354959 | 1.00 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Hydrochloric Acid SCHEMBL1507689 | 0.99 | EGFR (0.98) | EGFRERBB2GAKKDRILK | |
| Hydrochloric Acid SCHEMBL1507491 | 0.99 | EGFR (0.98) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL29120903 | 0.95 | EGFR (0.96) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL3667407 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL8413 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL29351329 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL30362833 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | claimed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | claimed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | claimed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | claimed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| JP-2011513427-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2010045344-A1 | COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2010045345-A2 | TREATMENT METHOD | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| US-RE41065-E1 | Alkynl and azido-substituted 4-anilinoquinazolines | PFIZER, INC. (US) | 2009-12-29 | — | — | US | claimed |
| WO-2009111691-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080175797-A1 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-07-24 | — | — | US | claimed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | claimed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | claimed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885GAK 1055/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885GAK 1055/4885 |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885GAK 1255/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885GAK 1255/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ERBB2 3/4885GAK 1255/4885 |
| US-20080175797-A1 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | EGFR, MUC1, OGFR | EGFR 1/4885ERBB2 6/4885GAK 1209/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ERBB2 1/4885GAK 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.